Published in PLoS One on November 18, 2009
Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med (2011) 9.90
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97
High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov (2011) 5.30
Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood (2010) 4.96
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet (2013) 4.48
Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev (2012) 3.44
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol (2011) 3.43
Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med (2014) 3.18
Clinical implications of the cancer genome. J Clin Oncol (2010) 3.11
Somatic activation of AKT3 causes hemispheric developmental brain malformations. Neuron (2012) 2.84
Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol (2013) 2.59
Next-generation sequencing for cancer diagnostics: a practical perspective. Clin Biochem Rev (2011) 2.31
Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variation. Genome Res (2013) 2.29
Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res (2012) 2.26
Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. J Mol Diagn (2013) 2.20
BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One (2011) 2.04
Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res (2011) 1.80
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood (2014) 1.79
Classifying human brain tumors by lipid imaging with mass spectrometry. Cancer Res (2011) 1.71
Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nat Biotechnol (2014) 1.71
EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol (2012) 1.71
Detecting somatic genetic alterations in tumor specimens by exon capture and massively parallel sequencing. J Vis Exp (2013) 1.68
CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res (2014) 1.66
AKT inhibitors promote cell death in cervical cancer through disruption of mTOR signaling and glucose uptake. PLoS One (2014) 1.62
Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus. J Clin Invest (2012) 1.61
Detection of low prevalence somatic mutations in solid tumors with ultra-deep targeted sequencing. Genome Biol (2011) 1.60
Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet (2014) 1.58
Taxonomy of breast cancer based on normal cell phenotype predicts outcome. J Clin Invest (2014) 1.58
Overcoming implementation challenges of personalized cancer therapy. Nat Rev Clin Oncol (2012) 1.56
Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. BMC Med Genomics (2014) 1.53
Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. J Mol Diagn (2011) 1.53
Existing and emerging technologies for tumor genomic profiling. J Clin Oncol (2013) 1.52
Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer (2013) 1.52
EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin Cancer Res (2011) 1.50
PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res (2010) 1.49
HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Res (2010) 1.48
Clinical analysis and interpretation of cancer genome data. J Clin Oncol (2013) 1.44
Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors. Elife (2015) 1.42
Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. J Natl Cancer Inst (2013) 1.38
Screening for germline EGFR T790M mutations through lung cancer genotyping. J Thorac Oncol (2012) 1.37
Building a personalized medicine infrastructure at a major cancer center. J Clin Oncol (2013) 1.36
Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma. BMC Cancer (2011) 1.36
RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg (2013) 1.34
Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol (2012) 1.33
High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma. PLoS One (2012) 1.32
Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine. Genome Med (2014) 1.31
High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. Blood (2011) 1.28
High throughput interrogation of somatic mutations in high grade serous cancer of the ovary. PLoS One (2011) 1.28
Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One (2012) 1.27
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat (2012) 1.26
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. J Mol Diagn (2014) 1.21
Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood (2013) 1.21
Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Mol Cancer (2012) 1.18
Systematic assessment of analytical methods for drug sensitivity prediction from cancer cell line data. Pac Symp Biocomput (2014) 1.17
High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes. Cancer (2011) 1.13
mTOR inhibitors in advanced renal cell carcinoma. Hematol Oncol Clin North Am (2011) 1.12
Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. J Mol Diagn (2011) 1.11
SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat Med (2015) 1.10
Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing. PLoS One (2013) 1.10
High-throughput RNA sequencing of a formalin-fixed, paraffin-embedded autopsy lung tissue sample from the 1918 influenza pandemic. J Pathol (2013) 1.09
High-throughput genotyping in metastatic esophageal squamous cell carcinoma identifies phosphoinositide-3-kinase and BRAF mutations. PLoS One (2012) 1.09
Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. Oncotarget (2014) 1.08
Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges. Cancer Discov (2011) 1.07
Using genetics and genomics strategies to personalize therapy for cancer: focus on melanoma. Biochem Pharmacol (2010) 1.06
Tumour molecular profiling for deciding therapy-the French initiative. Nat Rev Clin Oncol (2012) 1.04
Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanisms. Oncotarget (2013) 1.04
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro Oncol (2012) 1.04
BRAF mutations in metanephric adenoma of the kidney. Eur Urol (2012) 1.02
Somatic variation and cancer: therapies lost in the mix. Hum Genet (2011) 0.99
Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer. BMC Cancer (2013) 0.99
High-throughput sequencing and copy number variation detection using formalin fixed embedded tissue in metastatic gastric cancer. PLoS One (2014) 0.97
MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines. Oncogene (2013) 0.97
Genomic Characterization of Non-Small-Cell Lung Cancer in African Americans by Targeted Massively Parallel Sequencing. J Clin Oncol (2015) 0.96
FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med (2014) 0.95
The Stream algorithm: computationally efficient ridge-regression via Bayesian model averaging, and applications to pharmacogenomic prediction of cancer cell line sensitivity. Pac Symp Biocomput (2014) 0.95
A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice. Oncologist (2014) 0.93
Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma. Mol Cancer Ther (2012) 0.92
Genotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1. PLoS One (2014) 0.92
High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated. PLoS One (2012) 0.91
Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro Oncol (2015) 0.89
Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatr Blood Cancer (2014) 0.89
Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequency. PLoS One (2013) 0.88
Designing a high-throughput somatic mutation profiling panel specifically for gynaecological cancers. PLoS One (2014) 0.88
Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutations. Histopathology (2013) 0.88
Evaluation of ultra-deep targeted sequencing for personalized breast cancer care. Breast Cancer Res (2013) 0.88
Analysis and comparison of somatic mutations in paired primary and recurrent epithelial ovarian cancer samples. PLoS One (2014) 0.88
Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors. Pediatr Blood Cancer (2012) 0.87
Will kinase inhibitors make it as glioblastoma drugs? Curr Top Microbiol Immunol (2012) 0.87
Current Challenges in Glioblastoma: Intratumour Heterogeneity, Residual Disease, and Models to Predict Disease Recurrence. Front Oncol (2015) 0.87
A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. Neuro Oncol (2017) 0.86
Pten loss in Olig2 expressing neural progenitor cells and oligodendrocytes leads to interneuron dysplasia and leukodystrophy. Stem Cells (2014) 0.86
Mouse hospital and co-clinical trial project--from bench to bedside. Nat Rev Clin Oncol (2015) 0.86
EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant data. Transl Lung Cancer Res (2013) 0.86
Therapeutic potential of stem cells expressing suicide genes that selectively target human breast cancer cells: evidence that they exert tumoricidal effects via tumor tropism (review). Int J Oncol (2012) 0.86
Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma. Mol Cancer Ther (2014) 0.86
Gene and drug matrix for personalized cancer therapy. Nat Rev Drug Discov (2010) 0.86
Pediatric low-grade gliomas: how modern biology reshapes the clinical field. Biochim Biophys Acta (2014) 0.86
The sequence of the human genome. Science (2001) 101.55
Accurate whole human genome sequencing using reversible terminator chemistry. Nature (2008) 90.20
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 33.85
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 27.35
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res (2006) 13.98
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature (2007) 10.98
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol (2005) 9.95
Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science (1984) 9.64
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol (2007) 9.29
Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature (1983) 8.18
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest (2008) 3.98
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol (2009) 3.48
Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol (2009) 3.32
Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol (2008) 2.61
Combinatorial patterns of somatic gene mutations in cancer. FASEB J (2008) 2.40
Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res (2005) 2.13
PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations. Hum Pathol (2006) 1.47
Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. Pharmacology (2006) 1.41
Pilocytic astrocytomas do not show most of the genetic changes commonly seen in diffuse astrocytomas. Histopathology (2000) 1.23
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell (2006) 18.81
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature (2007) 15.20
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol (2003) 11.33
PDGFRA activating mutations in gastrointestinal stromal tumors. Science (2003) 11.11
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (2007) 10.60
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol (2011) 9.60
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41
p16INK4a induces an age-dependent decline in islet regenerative potential. Nature (2006) 9.09
Gene regulation and DNA damage in the ageing human brain. Nature (2004) 9.01
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49
Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46
Highly recurrent TERT promoter mutations in human melanoma. Science (2013) 8.40
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA (2003) 8.07
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature (2011) 8.03
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell (2007) 7.60
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res (2002) 7.29
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet (2009) 6.99
Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med (2006) 6.96
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet (2011) 6.89
Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer (2012) 6.82
Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature (2008) 6.80
Ductal carcinoma in situ of the breast. N Engl J Med (2004) 6.63
A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol (2004) 6.61
MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell (2009) 6.55
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol (2008) 6.43
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature (2008) 6.24
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10